Guidelines
Dual Vaccination

Dual Vaccination

Vaccine

PCV‐13⁽²⁾⁽³⁾ x single dose, followed by PPSV‐23⁽²⁾ 8 weeks later

Target Population

  • Asplenic
  • Sickle cell disease
  • Congenital immunodeficiencies
  • HIV
  • Corticosteroids
  • Chemotherapy
  • Radiation
  • SOT
  • Biologics
  • Malignancy
  • Nephrotic syndrome
  • HSCT*

*Patients post‐hematopoietic stem cell transplant (HSCT) should receive 3 doses of PCV‐13⁽²⁾⁽³⁾, spaced apart by 4 weeks each, starting 3‐9 months after transplant followed by PPSV‐23⁽²⁾ 12‐18 months post‐transplant.

PPSV-23 Booster

PPSV‐23⁽²⁾ booster x 1 recommended ≥5 years after initial pneumococcal vaccination

Vaccination Footnotes

(1) Live attenuated vaccine (2) Inactive or component vaccine (3)

Only covered by MSP for certain indications

PPSV‐23: 23 valent pneumococcal polysaccharide vaccine PCV‐13: 13 valent pneumococcal conjugate vaccine